Concord Biotech has announced the successful completion of an inspection conducted by Brazil's health regulatory authority, ANVISA, at its Active Pharmaceutical Ingredient (API) manufacturing facility located in Limbasi, Gujarat. The inspection was carried out from June 8 to June 12, 2026, and concluded successfully.

The company stated that the successful outcome of the ANVISA inspection marks an important milestone in its global growth strategy. The achievement reinforces Concord Biotech's commitment to maintaining the highest standards of quality, compliance, and regulatory excellence across its manufacturing operations.

According to the company, the inspection outcome is expected to strengthen its global manufacturing and regulatory footprint while supporting its international expansion plans. The development is particularly significant as it enhances Concord Biotech's access to Brazil, one of the world's largest pharmaceutical markets, and creates opportunities to expand the reach of its high-quality API products across key global geographies.